Key result
The presence of kidney disease was associated with a higher likelihood of receiving CCB/ARB combination therapy compared to CCB monotherapy, though guideline-suggested diuretic use for heart failure was rare.
Observational (n=182,025)
While Japanese patients with ischemic heart disease and kidney disease are frequently prescribed guideline-concordant CCB/ARB combination therapy, prescription patterns for heart failure patients show poor compliance with guideline recommendations for diuretic-based combinations.
Answers are grounded in this paper and cite their sources.
Highlights a concerning gap in guideline-directed medical therapy for heart failure; leaves open the need for.
Kidney disease (KD) is a serious risk factor for cardiovascular event, and it is important to protect the heart and kidneys during treatment of the high blood pressure to prevent cardiovascular event. Japanese guideline (JSH2014) suggests using combination therapy to reduce the risk of comorbidities rather than high-dose monotherapy for the patients with cardiovascular disease and KD. Therefore, the present study assessed antihypertensive prescription patterns in Japanese patients with ischemic heart disease related diseases (IHDRD) and KD, and evaluated whether the prescription patterns match with the guideline-suggested therapies by analyzing the national insurance claims database (NDB). We extracted antihypertensive prescription patterns among Japanese IHDRD patients from the data of October 2011 of NDB, and examined the effect of KD on the prescription patterns. The number of prescribed antihypertensive was associated with KD among patients regardless of IHDRD. Patients with IHDRD and KD were more frequently prescribed combination therapy (calcium channel blockers/angiotensin II receptor blockers) than the calcium channel blocker monotherapy, based on the JSH2014. On the other hand, we did not observe the standard use of diuretics for patients with heart failure, which is suggested by the JSH2014. These findings suggested that patients with IHDRD and KD were frequently prescribed combination therapy to achieve its cardioprotective and renoprotective effects, according to the JSH2014, but the prescription profile to the patients with heart failure didn't match that of guideline-suggested therapies. This study provided a clinically important information and demonstrated the utility of NDB for compliance assessment for therapeutics guideline.
No takes yet. Share an insight, caveat, or question.
Hagiwara et al. (2017) conducted an observational in Hypertension with ischemic heart disease related diseases and/or kidney disease (n=182,025). Kidney disease comorbidity vs. Patients without kidney disease was evaluated on Prescription of CCB/ARB combination therapy versus CCB monotherapy in outpatients with heart failure (OR 1.61, 95% CI 1.44-1.80, p=<0.05). The presence of kidney disease was associated with a higher likelihood of receiving CCB/ARB combination therapy compared to CCB monotherapy, though guideline-suggested diuretic use for heart failure was rare.
Synapse has enriched 10 related papers. Consider them for comparative context: